INTELWAVE HEART RATE VARIABILITY SYSTEM, VERSION 1.0
Applicant
Intelwave, LLC
Product Code
DPS · Cardiovascular
Decision Date
Oct 27, 2006
Decision
SESE
Submission Type
Traditional
Regulation
21 CFR 870.2340
Device Class
Class 2
Attributes
Software as a Medical Device
Intended Use
The Intelwave 1.0 System is intended for use in heart rate variability (HRV) measurements in response to paced respiration and controlled exercises.
Device Story
Computer-based system for HRV measurement; inputs R-wave trigger data from FDA-compliant ECG device; performs automated quantitative HRV analysis; presents results via computer interface; includes patient data management; used by clinicians to assess HRV during paced respiration and controlled exercise; output aids clinical decision-making regarding cardiac autonomic function.
Clinical Evidence
Bench testing only. Performance evaluation included comparison against the Holter Plus system and validation of HRV assessment reliability. Device designed to comply with ANSI/AAMI EC57:1998/(R)2003 for cardiac rhythm and ST-segment measurement algorithms.
Indicated for heart rate variability (HRV) measurements in response to paced respiration and controlled exercises. No specific patient population, age, or gender contraindications provided.
Regulatory Classification
Identification
An electrocardiograph is a device used to process the electrical signal transmitted through two or more electrocardiograph electrodes and to produce a visual display of the electrical signal produced by the heart.
K012712 — NORAV HOLTER SYSTEM, MODEL NH-300 V1.07 · Norav Medical , Ltd. · May 8, 2002
K991831 — BMT ANSCORE HEALTH MANAGEMENT SYSTEM, MODEL 1.1 · Boston Medical Technologies, Inc. · Jun 11, 1999
K080884 — QHRV 1 - HEALTH ASSESSMENT SYSTEM · Medtechs, LLC · Apr 11, 2008
K042799 — QRS-CARD CARDIOLOGY SUITE · Pulse Biomedical, Inc. · Oct 22, 2004
K012825 — HEARTTRENDS · Lev-El, Ltd. · Mar 19, 2002
Submission Summary (Full Text)
{0}------------------------------------------------
K062068
pg 1 of 2
OCT 2 7 2006
## 510(k) SUMMARY
### INTELWAVE HEART RATE VARIABILITY SYSTEM
#### 1. Submitter Information
This 510(k) summary of safety and effectiveness information is submitted in accordance with the requirements of Section 513(i)(3) of the Federal Food, Drug, and Cosmetic Act and 21 C.F.R. 807.92.
The submitter of this premarket notification is: Alexander Riftine, Ph.D. President Intelwave, LLC 1090 King Georges Post Road Suite 1004 Edison, NJ 08837 Tel: (732) 738 - 8800 (732) 738 - 8877 Fax:
This summary was prepared on June 07, 2006.
#### 2. Name of device.
The name of the device is the Intelwave Heart Rate Variability System. The common name is the ECG monitor Heart Rate Variability System. The classification name is Electrocardiograph. 21 C.F.R. 870.2340.
#### 3. Predicate device.
Intelwave 1.0 system is substantially equivalent to the following predicate devices:
- 1. Anscore™ Health Management System (510(k) K010955).
- 2. Holter PlusTM Ambulatory ECG Analysis System (510(k) K042463).
- 3. ANX 3.0 Respiratory and cardiac spectral frequency signal (510(k) K941252).
- 4. HeROTM HRV analysis system (510(k) K021230).
CONFIDENTIAL
{1}------------------------------------------------
#### 4. Device Description:
The Intelwave 1.0 System is a computer-based system for measurement of Heart Rate Variability (HRV) in response to paced respiration and controlled exercises.
The system performs a fully automated quantitative analysis of HRV based on data collected by an FDA-compliant R Wave Trigger device recommended or supplied by Intelwave. The system presents the results to the physician through a computer-based user interface. The system has patient data management capability.
#### Technological characteristics. 5.
The measurement technology and the method of Heart Rate Variability analysis are essentially the same as those of the other legally marketed predicate devices.
#### 6. Intended use:
The Intelwave 1.0 System is intended for use in heart rate variability (HRV) measurements in response to paced respiration and controlled exercises.
### 7. Performance data.
This product is designed to comply with ANSI/AAMI EC57: 1998/(R) 2003 "Testing and reporting performance results of cardiac rhythm and ST-segment measurement algorithms". Performance testing of the Intelwave system included:
- 1) Comparison Performance Evaluation. Testing against the Holter Plus TM system.
- 2) Validation of reliability of HRV assessment by the Intelwave system.
{2}------------------------------------------------
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
OCT 2 7 2006
IntelWave, LLC c/o Alexander Riftine, PhD 1090 King Georges Post Rd Ste 1004 Edison, NJ, 08837
Re: K062068
Intelwave Heart Rate Variability System, Version 1.0 Regulation Number: 21 CFR 870.2340 Regulation Name: Electocardiograph Regulatory Class: Class II Product Code: DPS Dated: October 4, 2006 Received: September 29, 2006
Dear Dr. Riftine:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act
{3}------------------------------------------------
Page 2 - Dr. Alexander Riftine
or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Bhimmon for
Bram D. Zuckerman, M.D. Director . Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
# Indications for Use
510(k) Number (if known):
K062068
Device Name:
Intelwave 1.0
Indications For Use:
The Intelwave 1.0 System is intended for use in Heart Rate Variability (HRV) measurements in response to paced respiration and controlled exercises.
Prescription Use × (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
B. Hummer
(Division Sign Off)
on Sign-Off) Division of Cardiovascular Devices 510(k) Number
Panel 1
/
Sort by
Ready
Predicate graph will load when search results are available.
Embedding visualization will load when search results are available.
PDF viewer will load when search results are available.
Loading panels...
Select an item from Submissions
Click any panel, subpart, regulation, product code, or device to see details here.
Section Matches
Results will appear here.
Product Code Matches
Results will appear here.
Special Control Matches
Results will appear here.
Loading collections...
Loading
My Alerts
You will receive email notifications based on the filters and frequency you set for each alert.